Treating IgA nephropathy has long been about slowing kidney damage rather than addressing what drives the disease. Trutakna changes that approach. Approved by the FDA for adults with primary IgA nephropathy (IgAN) at risk of disease progression, it is the first dual BAFF/APRIL inhibitor designed to target two important immune pathways at the same time.
By blocking both BAFF and APRIL, Trutakna reduces the production of the abnormal IgA1 antibodies responsible for immune complex formation and kidney injury. The result is lower proteinuria and a therapy that goes beyond symptom management to modify disease activity. It is also self-administered as a subcutaneous injection, offering patients a more convenient treatment option.
As adoption grows, Trutakna is likely to become an important comparator in nephrology and autoimmune disease research. Keeping track of its exclusivity timeline, commercial uptake, and availability will be valuable for clinical trial planning and first-to-file strategies.
